Abstract. The MAP-2 isoform containing exon 13 (MAP-2e) is expressed in human fetal development as early as 15 gestational weeks and parallels oligodendrocyte maturation. MAP-2e is down-regulated following myelination and is expressed in few cells in the adult central nervous system (CNS). To determine whether CNS tumors express MAP-2e, we screened 122 archival, paraffin-embedded adult and pediatric tumors of the CNS and non-CNS. All oligodendrogliomas were positive and extensive staining was observed in glioblastomas, various malignant gliomas and dysembryoplastic neuroepithelial tumors. MAP-2e was not expressed in non-CNS tumors or neuroblastomas. Thus, neuroectodermal tumors that have glial characteristics express this developmental marker of immature glia. Analysis of oligodendrogliomas demonstrated numerous cell morphologies from round cells with no processes to cells with single or multiple processes. MAP-2e immunostaining also delineated tumor invasion into adjacent gray and white matter, indicating that MAP-2e appears to be a useful marker for examining the infiltration of malignant cells into surrounding tissue.
INTRODUCTION
Microtubule-associated protein-2 (MAP-2) is a family of heat-stable phosphoproteins expressed predominantly in the cell body and dendrites of neurons of the central nervous system (CNS) (1) (2) (3) (4) . It is also expressed in oligodendrocytes (5) , in dorsal root ganglion (DRG) of the peripheral nervous system (PNS) (6) , in reactive glia (7, 8) , and a number of cell types in the testis (9) . In neurons, 3 major MAP-2 isoforms (MAP-2a, MAP-2b, and MAP2c) are differentially expressed during the development of the nervous system and have an important role in microtubule dynamics. Several other MAP-2 cDNA clones that correspond to novel MAP-2 transcripts expressed in the CNS and PNS have been characterized and result from the alternative splicing of a single MAP-2 gene consisting of 20 exons (1, 10) .
One of the many splice variants of MAP-2 contains exon 13. This MAP-2 form is expressed during the development of the human CNS, where it is found in the cell bodies and processes of oligodendrocytes, but not in the myelin sheath itself (5) . The variant is down-regulated during oligodendrocyte development (5, 15) . By RT-PCR we have determined that the form expressed in oligodendrocytes from human fetal spinal cord is a high molecular This work was supported by NIH NS17125 (JEG), NS38102 (BSZ) and National MS Society RG3020-01 (BSZ).
weight form with the inclusion of exons 5-7, 9-20 (unpublished data, C. Andorfer, Albert Einstein College of Medicine), eliminating exon 7A, which is expressed in the PNS (6) , and exon 8 shown to be encoded as part of MAP-2a (11) (12) (13) (14) . Previously, we referred to this clone as MAP-2ϩ13; however, we suggest renaming this MAP-2 form MAP-2e consistent with existing MAP-2 nomenclature.
In this study, we examined by immunocytochemical analysis whether MAP-2e was expressed by pediatric and adult CNS neuroectodermal neoplasms, and compared its expression to that in non-CNS neoplasms. CNS tumors, particularly oligodendrogliomas and glioblastomas, stained intensely in the large majority of tumor cells, while other CNS tumors stained variably and non-CNS neoplasms were negative. Since MAP-2e is localized to cell processes as well as somas, the immunostaining revealed details of cell morphology undetectable with routine stains. This localization allowed us to examine such features as process orientation and branching in neoplastic cells infiltrating normal brain.
MATERIALS AND METHODS

Tumors
Sections of biopsies were obtained from the archives of the Neuropathology Divisions of the Pathology Departments of Albert Einstein College of Medicine, Montefiore Medical Center, and Columbia University. Four to 7 m formalin-fixed, paraffin-embedded sections were stained with hematoxylin and eosin (H&E). All biopsies were evaluated and classified by one of the neuropathologists (SCL, JEG, JL) prior to the onset of the study. A wide variety of adult and pediatric primary neoplasms, metastases to the CNS, and non-neoplastic conditions (Tables  1, 2) were examined. 
Immunocytochemistry
Prior to immunostaining, paraffin sections were rehydrated, microwaved in distilled water for antigen retrieval (7 min, power 7), incubated with 3% hydrogen peroxide in 1ϫ TBS and 0.25% Triton X-100 for 30 min, and blocked in 5% nonfat dry milk in 1ϫ TBS for 1 h. Sections were incubated with a monoclonal antibody (mAb 13.10 (1:10), mouse IgG1) specific for MAP-2e overnight at 4ЊC, followed by goat, anti-mouse biotin streptavidin labeled secondary antibody (Vectastain kit, Vector Laboratories, Burlingame, CA). Visualization was by diaminobenzidine (DAB) and light microscopy. Absorption with the synthetic peptides was as previously described (5) . Prolonged boiling (20 min) did not alter the status of tumors that were initially negative after the standard 7-min antigen retrieval step. Immunopositivity was evaluated semi-quantitatively according to the percentage of tumor cells labeled as follows: 0: 0%; 1: less than 10%; 2: less than 50%; 3: more than 50%.
Measurements of Process Orientation of Infiltrating Tumor Cells
We examined cortical zones that had been infiltrated by an oligodendroglioma in one case. The MAP-2e-immunostained slide was projected and a line perpendicular to the pial surface was drawn on the projection. All tumor cells in the field that displayed both a nucleus and a process were selected and the angle between the direction of the process and the perpendicular (radial) was measured. The majority of the processes were linear, although some showed small curvatures, particularly near the tip. In such cases, we estimated the direction of the process by drawing a line from the cell body through the maximum amount of process possible. The rare cell that displayed an angled process was not included in the measurements. The measurements of angles were placed in a series of bins, corresponding to 10-degree intervals from 0 to 90, with 0 representing radial and 90 representing tangential or parallel to the pial surface. Note that cells oriented toward the pial surface would fall into the 0 to 10 degree bin, as would cells with processes oriented in the opposite direction (180 degrees away from the direction of the pia).
RESULTS
Primary Tumors of Neuroectodermal Origin Express MAP-2e
One hundred and twenty-two pediatric and adult tumors and 6 non-neoplastic conditions were examined for MAP2e expression (Tables 1, 2 * These 2 samples were the primary and the recurrent ones from 1 patient. Metastatic carcinomas used in this study included renal cell, small cell of the lung, germ cell tumor, and carcinoid. Sarcomas included Ewing's sarcoma, undifferentiated sarcoma, and a rhabdomyosarcoma. All pediatric tumors were from individuals 18 years of age and under (range 2-18 years) with the exception of 1 individual who presented with a PNET at age 33. Abbreviations: PNET ϭ peripheral neuroectodermal tumor; GB ϭ glioblastomas; DNT ϭ Dysembryoplastic neuroepithelial tumor.
of neuroectodermal nature such as low-grade diffuse astrocytomas, neurocytomas, paragangliomas, ganglioglioma, dysembryoplastic neuroepithelial tumors (DNTs), and pineoblastoma were also positive, but usually only focally. Non-neuroectodermal tumors, metastatic tumors, and nonneoplastic conditions were negative.
MAP-2e Expression in Oligodendrogliomas Reveals
Cell Morphologies and Patterns of Infiltration
All oligodendrogliomas, including 6 anaplastic subtypes, expressed MAP-2e immunoreactivity in nearly all of the tumor cells. The cytoplasmic staining delineated a range of cell morphologies. Some of the MAP-2e-positive cells appeared round with no processes, particularly in the densely packed areas of the tumors (Fig. 1A) . Other cells displayed single or multiple processes (Fig. 1C) , particularly in areas in which the oligodendroglioma infiltrated cortex. In some cases, the processes were many lengths longer than the cell body (Fig. 2B) . In addition, minigemistocytes also showed cytoplasmic staining (Fig.  1D) . The specificity of MAP-2e immunoreactivity was confirmed by incubating the antibody with a synthetic peptide to exon 13 sequence, which eliminated all of the immunostaining (Fig. 1B) . The same results were obtained when the antibody was preincubated with GSTfusion from exon 13 encoded sequences (data not shown).
MAP-2e immunostaining was especially useful in visualizing tumor cells that had infiltrated into adjacent gray and white matter. Routine H&E only revealed tumor nuclei in the cortex. However, immunostaining revealed both the distribution and orientation of tumor cells, which appeared throughout all cortical layers, collecting in some sub-pial zones as secondary structures (Fig. 2A) . The majority of the tumor cells appeared unipolar. We examined such cells in the cortex in detail in an infiltrating oligodendroglioma and measured the orientation of the processes relative to the pial surface. The orientation was skewed towards a radial direction (Fig. 2B, E) , suggesting that tumor cells were migrating perpendicular to the pial surface, perhaps along specific radial pathways. We observed tumor cells with radially oriented processes directed toward the pia, as well as cells with processes oriented in the opposite direction, toward the underlying white matter. In addition, the measures revealed a smaller number of cells whose processes were oriented tangentially (Fig. 2E) . The processes tended to be linear rather than bent or coiled, again suggesting that they were oriented by interaction with such linear structures as axons and dendrites or blood vessels. Furthermore, immunostaining demonstrated processes of satellite tumor cells, which wrapped the cell bodies of neurons (Fig. 2C) . In white matter, tumor cells extended processes parallel to the axon bundles (Fig. 2D) , suggesting migration along axon tracts.
Glioblastomas (GBs) and Astrocytomas Are Usually MAP-2e-Positive
Second to oligodendrogliomas, GBs had a high frequency of MAP-2e immunoreactivity (16/23). The majority of the tumor cells demonstrated extensive, intense MAP-2e staining, including small round cells, gemistocytic cells, and cells with many processes (Fig. 3A, B) . MAP-2e immunostaining was detected in tumor cells that had infiltrated into adjacent gray and white matter and processes oriented toward the pial surface were apparent (Fig. 3B) . We also observed rosette-like formations, in which nuclei were arranged around a central zone composed of radially oriented cell processes (Fig. 3C) . We believe this architecture is related to pseudopalisading necrosis, since we observed such radial projections into central necrotic zones as well.
Nineteen astrocytomas consisting of 2 anaplastic, 10 low-grade and 7 pilocytic astrocytomas were examined for MAP-2e immunoreactivity. Tumor cells within the anaplastic astrocytomas were diffusely positive (Fig. 3D) , while the low-grade diffuse astrocytomas showed variable focal staining (Fig. 3E) . Pilocytic astrocytomas contained MAP-2e-positive processes (Fig. 3F) .
Other CNS Tumors
Ependymomas were also MAP-2e-immunopositive. The majority of the tumor cells were positive in some cases (Fig. 4A) . In 1 ependymoma, infiltrating tumor cells in the cerebellar cortex showed radially oriented processes as shown in the other infiltrating gliomas (Fig.  4B) . Seven of 19 peripheral neuroectodermal tumors (PNETs) were positive, but in each case only fewer than 10% of the cells were MAP-2e-immunoreactive (Fig.  4C) . A ganglioglioma showed MAP-2e immunoreactivity only in the astrocytic component (data not shown).
We examined 8 neurocytomas from 7 patients, including a recurrent sample from one of the patients with a history of multiple recurrences. All the specimens were synaptophysin-positive. While most of the samples showed MAP-2e immunoreactivity in only a few cells (Fig. 4D) , the recurrent case demonstrated diffuse staining in both primary and recurrent tumors (Fig. 4E) . No positive cells were observed in CNS lymphoma, meningioma, or metastatic neoplasms.
The Small Cell Population (''Oligodendrocyte-Like Cells'') In a DNT Is MAP-2e-Positive
In DNTs, MAP-2e positivity was present in the small, round cells of the cystic areas (Fig. 4F ), but not in the ''floating'' neurons. In the surrounding neuropil, large numbers of positive cells with small, round nuclei and few processes were present (Fig. 4G) . These cells had a similar nuclear morphology to those in cystic regions. MAP-2e-immunostaining thus clearly demonstrated a general increase in the number of these internodular ''oligodendrocyte-like cells'' over a larger area than just the cystic region itself.
DISCUSSION
We have determined that MAP-2e immunostaining is specific for CNS neuroectodermal tumors, especially those with glial characteristics. However, in the glial tumors the immunopositivity was observed regardless of either tumor type or grade, thus suggesting MAP-2e staining is not of prognostic value. All oligodendrogliomas were positive; extensive staining was also observed in glioblastomas, astrocytomas, and other malignant gliomas. The small cell component of a DNT expressed MAP-2e, consistent with their characterization as glialor oligodendrocyte-like cells. Little or no MAP-2e was found in PNETs or in the majority of neurocytomas, or in undifferentiated childhood peripheral tumors such as neuroblastomas and small blue cell tumors, including Ewing's sarcoma believed to have neuroblastic characteristics, or in rhabdomyosarcoma and lymphoma/leukemia.
Cell Morphologies and Tumor Architecture Revealed by MAP-2e Immunostaining
The anti-MAP-2e antibody demonstrated numerous cell morphologies from round cells with no processes to cells with single or multiple processes; in some cases the processes were many lengths longer than the cell body. This is in contrast to the appearance of oligodendrogliomas in routine H&E stains where processes cannot be appreciated, but highly reminiscent of early studies of oligodendrogliomas using heavy metal impregnations (16, 17) . Process extension was particularly notable in areas of cortical infiltration, which was observed in diverse glioma types such as oligodendrogliomas, astrocytic tumors, and ependymomas. The pronounced radial arrangement of tumor cell processes suggests that glioma cells migrate along preferred substrates with radial orientations. Preliminary studies show that at least some of these radial structures correspond to the apical dendrites of pyramidal neurons (unpublished observations). The tangential orientation observed in the cortex and especially in subpial structures may represent migration along intracortical axon bundles.
These unipolar tumor cells bear a strong resemblance to migrating glial progenitors in the developing mammalian CNS (18) . In this dynamic study of progenitor migration in the rat forebrain we observed that cells migrated in the direction of the leading process. Assuming that the glioma cells are also migrating in the direction of the leading process, we infer that many are migrating toward the pia, but others migrate in the opposite direction, perhaps having reversed themselves after entering the cortex.
Expression of MAP-2e in Glial vs Neuronal Neoplasms
Regarding neuronal tumors, all the neurocytomas showed only focal immunoreaction to MAP-2e except samples from a patient with a history of multiple recurrences. The case showed a diffuse staining both in the primary and the recurrent tumors. Histopathologically, both specimens from this patient looked similar and showed moderate nuclear atypia and increased mitotic rate, which were never seen in the rest of the cases. Because of the limited number of the cases, we are not certain at this point if the findings reflect the biological behavior of this tumor type. However, it is worth further investigating if the degree of MAP-2e-expression is of prognostic value in neurocytomas. Furthermore, given that the majority of neurocytomas were only focally immunopositive for MAP-2e, MAP-2e-immunostaining would be of potential use in the differential diagnosis between neurocytomas and oligodendrogliomas because all of the latter were diffusely positive for MAP-2e.
Regarding DNT, we did not observe any MAP-2e-immunopositivity either in the ''floating neurons'' in the cystic areas or mature neurons in the intercystic cortex. However, the ''oligodendrocyte-like cells'' with round, small nuclei were positive. The nature of these cells remains controversial (19) , because although they express a panel of neuronal markers (20) (21) (22) , it has also been reported that they show oligodendrocytic differentiation (23) expression along neuronal differentiation in the ''oligodendrocyte-like cells'' or a glial character of these cells should be investigated further.
A ganglioglioma showed MAP-2e immunopositivity only in the astrocytic component, while the neoplastic neurons were totally negative. The findings indicate that MAP-2e is not generally expressed in well-differentiated neuronal neoplastic cells.
Specificity of MAP-2e for Neoplastic Cells
Previous studies with normal human adult brain and spinal cord sections obtained from autopsy or surgical materials revealed very few MAP-2e-positive cells in gray and white matter (5, 15) . These were small cells with round to oval nuclei and generally few processes but they never showed the elongated, unipolar morphology of infiltrating neoplastic cells. Our preliminary characterizations based on histology and antigen expression suggest that these cells in the normal adult brain are not astrocytes, neurons, myelinating oligodendrocytes, or microglia (Suzuki et al, manuscript in preparation). In normal human developing fetal forebrain and spinal cord, however, MAP-2e-immunostaining revealed numerous positive cells with long, simple processes, presumably representing a population of glial progenitors (5). Our previous study in multiple sclerosis lesions indicated that MAP-2e was expressed in remyelinating oligodendrocytes but not in reactive astrocytes. Thus, MAP-2e expression is not specific for tumor tissue, but it may be useful in determining the extent of infiltration of gliomas into the adjacent brain tissue. In normal development and in some non-neoplastic pathological conditions of the CNS, as well as in glial brain tumors, this early microtubule-associated protein may be beneficial for cytoskeletal dynamics, including process extension and migration.
MAP-2e vs Other MAP-2 Splice Variants
Blumcke et al recently reported the expression of MAP-2 in a large series of human neuroepithelial tumors using antibody AP14, which recognizes high MW MAP-2, and AP18 and clone C, which bind to both high and low MW MAP-2 isoforms (24) . In addition to lacking the specificity of the antibody generated to exon 13-encoded sequence, these antibodies recognize neurons as well as the tumor and detect multiple MAP-2 forms. However, since MAP-2e belongs to the high MW MAP-2 isoform group, there should be overlap between the pattern of staining with the MAP-2e antibody and other MAP-2 antibodies. Indeed, Blumcke et al showed constant and strong staining in oligodendrogliomas and variable immunoreactivity in other gliomas, which is consistent with our MAP-2e staining. They also showed MAP-2e mRNA expression in oligodendrogliomas and astrocytomas by RT-PCR. Nonetheless, there are differences between some of their findings and ours. Firstly, the specificity of our antibody demonstrates the infiltrating population of tumor cells, especially in the cortex. This is not apparent in the Blumcke study because the other anti-MAP-2 antibodies react with the MAP-2 forms in the existing dendrites and neuronal cell bodies, creating a high background against which it would be difficult to recognize tumor cells. Secondly, Blumcke et al did not observe any MAP-2 expression in ependymomas, DNTs, and central neurocytomas. In contrast, our MAP-2e antibody stained at least a fraction of tumor cells in these tumor types. There are some possible explanations for this discrepancy: 1) different tissue processing caused the inconsistent results, and 2) these tumors mainly express the MAP-2e isoform and the titer of our antibody is high enough to detect what might be a relatively low-level expression of MAP-2e. The expression level of MAP-2e relative to that of other MAP-2 isoforms in a panel of neuroectodermal tumors awaits further investigation.
